1. Home
  2. EXAS vs ROIV Comparison

EXAS vs ROIV Comparison

Compare EXAS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$103.89

Market Cap

19.7B

Sector

Health Care

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$27.78

Market Cap

20.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXAS
ROIV
Founded
1995
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.7B
20.7B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
EXAS
ROIV
Price
$103.89
$27.78
Analyst Decision
Hold
Strong Buy
Analyst Count
17
8
Target Price
$86.62
$27.56
AVG Volume (30 Days)
1.8M
4.6M
Earning Date
04-30-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
80.32
N/A
EPS
N/A
N/A
Revenue
$4,144,000.00
$29,053,000.00
Revenue This Year
$15.37
N/A
Revenue Next Year
$12.41
$594.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.88
$8.73
52 Week High
$104.02
$30.33

Technical Indicators

Market Signals
Indicator
EXAS
ROIV
Relative Strength Index (RSI) 61.72 50.92
Support Level $103.10 $26.94
Resistance Level N/A $27.94
Average True Range (ATR) 0.31 0.96
MACD -0.03 -0.36
Stochastic Oscillator 86.96 23.85

Price Performance

Historical Comparison
EXAS
ROIV

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: